This page is part of the Compendium of WHO Recommendations for Postpartum Family Planning, which is accessible here: srhr.org/postpartumfp
|Antiretroviral Therapy||Category||Clarifications/Special considerations|
|a) Nucleoside reverse transcriptase inhibitors (NRTIs)||Clarification:
Antiretroviral drugs have the potential to either decrease or increase the levels of steroid hormones in women using hormonal contraceptives.
Pharmacokinetic data suggest potential drug interactions between some antiretroviral drugs (particularly some NNRTIs and ritonavir-boosted PIs) and some hormonal contraceptives.
These interactions may reduce the effectiveness of the hormonal contraceptive.
|b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs)|
|c) Protease inhibitors (PIs)|
|Ritonavir-boosted atazanavir (ATV/r)||2|
|Ritonavir-boosted lopinavir (LPV/r)||2|
|Ritonavir-boosted darunavir (DRV/r)||2|
|d) Integrase inhibitors|